Search

Your search keyword '"Cerinic, M. Matucci"' showing total 107 results
Start Over Author "Cerinic, M. Matucci"
107 results on '"Cerinic, M. Matucci"'

1. Systemic sclerosis in the time of COVID-19

Author

Hoffmann-Vold, A.M., Distler, O., Bruni, C., Denton, C.P., Vries-Bouwstra, J. de, Cerinic, M. Matucci, Vonk, M.C., Gabrielli, A., Hoffmann-Vold, A.M., Distler, O., Bruni, C., Denton, C.P., Vries-Bouwstra, J. de, Cerinic, M. Matucci, Vonk, M.C., and Gabrielli, A.

Abstract

Item does not contain fulltext, The COVID-19 pandemic represents one of the biggest challenges of the 21st century. In addition to the general effect on society and health-care systems, patients with systemic sclerosis and their physicians face specific challenges related to the chronic nature of their disease, the involvement of multiple organs, and the use of immunosuppressive treatments. Data from registries and single centre cohorts indicate that the risk of contracting SARS-CoV-2 does not seem to increase substantially in people with systemic sclerosis; conversely, severe COVID-19 outcomes are seen more frequently in these patients than in the general population. Vaccination against SARS-CoV-2 is therefore highly recommended for patients with systemic sclerosis; however, no specific recommendations are available regarding the different vaccine platforms. Both patients and physicians should be aware that the effectiveness of vaccines might be reduced in patients taking immunosuppressive therapy, because antibody responses might be blunted, specifically in patients treated with rituximab and mycophenolate mofetil.

Published
2022

5. Cardiovascular magnetic resonance in autoimmune rheumatic diseases: a clinical consensus document by the European Association of Cardiovascular Imaging.

Author

Mavrogeni, S, Pepe, A, Nijveldt, R, Ntusi, N, Sierra-Galan, L M, Bratis, K, Wei, J, Mukherjee, M, Markousis-Mavrogenis, G, Gargani, L, Sade, L E, Ajmone-Marsan, N, Seferovic, P, Donal, E, Nurmohamed, M, Cerinic, M Matucci, Sfikakis, P, Kitas, G, Schwitter, J, and Lima, J A C

Subjects
RAYNAUD'S disease, ECHOCARDIOGRAPHY, CARDIOTOXICITY, HEART valve diseases, SARCOIDOSIS, BLOOD vessels, PERICARDITIS, PERICARDIAL effusion, CARDIOMYOPATHIES, PULMONARY hypertension, MYOCARDIAL ischemia, MAGNETIC resonance imaging, AUTOIMMUNE diseases, CARDIOVASCULAR diseases, SYSTEMIC scleroderma, MYOCARDIAL infarction, MEDICAL protocols, DIAGNOSTIC imaging, SPONDYLOARTHROPATHIES, RADIONUCLIDE imaging, CARDIAC tamponade, POSITRON emission tomography, RADIOPHARMACEUTICALS, RHEUMATISM, DEOXY sugars, COMPUTED tomography, CARDIOVASCULAR disease diagnosis, EARLY diagnosis, ALGORITHMS, IMMUNOTHERAPY, SYMPTOMS
Abstract

Autoimmune rheumatic diseases (ARDs) involve multiple organs including the heart and vasculature. Despite novel treatments, patients with ARDs still experience a reduced life expectancy, partly caused by the higher prevalence of cardiovascular disease (CVD). This includes CV inflammation, rhythm disturbances, perfusion abnormalities (ischaemia/infarction), dysregulation of vasoreactivity, myocardial fibrosis, coagulation abnormalities, pulmonary hypertension, valvular disease, and side-effects of immunomodulatory therapy. Currently, the evaluation of CV involvement in patients with ARDs is based on the assessment of cardiac symptoms, coupled with electrocardiography, blood testing, and echocardiography. However, CVD may not become overt until late in the course of the disease, thus potentially limiting the therapeutic window for intervention. More recently, cardiovascular magnetic resonance (CMR) has allowed for the early identification of pathophysiologic structural/functional alterations that take place before the onset of clinically overt CVD. CMR allows for detailed evaluation of biventricular function together with tissue characterization of vessels/myocardium in the same examination, yielding a reliable assessment of disease activity that might not be mirrored by blood biomarkers and other imaging modalities. Therefore, CMR provides diagnostic information that enables timely clinical decision-making and facilitates the tailoring of treatment to individual patients. Here we review the role of CMR in the early and accurate diagnosis of CVD in patients with ARDs compared with other non-invasive imaging modalities. Furthermore, we present a consensus-based decision algorithm for when a CMR study could be considered in patients with ARDs, together with a standardized study protocol. Lastly, we discuss the clinical implications of findings from a CMR examination. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

6. THE PSABio STUDY IN ITALY: A REAL-WORLD COMPARISON OF THE PERSISTENCE, EFFECTIVENESS AND SAFETY OF USTEKINUMAB AND TUMOUR NECROSIS FACTOR INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS

Author

Gremese, E., Ciccia, F., Selmi, C., Cuomo, G., Foti, R., Cerinic, M. Matucci, Conti, F., Fusaro, E., Guggino, G., Iannone, F., Delle Sedie, A., Perricone, R., Idolazzi, L., Moscato, P., Theander, E., Noel, W., Bergmans, P., Marelli, S., Gossec, L., and Smolen, J. S.

Subjects
Psortiatic arthritis biologic agent ustekinumab
Published
2021

7. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative

Author

Gossec, L, Paternotte, S, Aanerud, G J, Balanescu, A, Boumpas, D T, Carmona, L, de Wit, M, Dijkmans, B A C, Dougados, M, Englbrecht, M, Gogus, F, Heiberg, T, Hernandez, C, Kirwan, J R, Mola, E Martin, Cerinic, M Matucci, Otsa, K, Schett, G, Scholte-Voshaar, M, Sokka, T, von Krause, G, Wells, G A, and Kvien, T K

Published
2011
Full Text
View/download PDF

8. NLRP1 influences the systemic sclerosis phenotype: a new clue for the contribution of innate immunity in systemic sclerosis-related fibrosing alveolitis pathogenesis

Author

Dieudé, P, Guedj, M, Wipff, J, Ruiz, B, Riemekasten, G, Airo, P, Melchers, I, Hachulla, E, Cerinic, M Matucci, Diot, E, Hunzelmann, N, Caramaschi, P, Sibilia, J, Tiev, K, Mouthon, L, Riccieri, V, Cracowski, J L, Carpentier, P H, Distler, J, Amoura, Z, Tarner, I, Avouac, J, Meyer, O, Kahan, A, Boileau, C, and Allanore, Y

Published
2011
Full Text
View/download PDF

18. European multicentre study to define disease activity criteria for systemic sclerosis. * II. Identification of disease activity variables and development of preliminary activity indexes

Author

Valentini, G, Della Rossa, A, Bombardieri, S, Bencivelli, W, Silman, A J, DʼAngelo, S, Cerinic, M Matucci, Belch, J F, Black, C M, Bruhlmann, P, Czirják, L, De Luca, A, Drosos, A A, Ferri, C, Gabrielli, A, Giacomelli, R, Hayem, G, Inanc, M, McHugh, N J, Nielsen, H, Rosada, M, Scorza, R, Stork, J, Sysa, A, van den Hoogen, F H J, and Vlachoyiannopoulos, P J

Published
2001

19. European multicentre study to define disease activity criteria for systemic sclerosis. * I. Clinical and epidemiological features of 290 patients from 19 centres

Author

Della Rossa, A, Valentini, G, Bombardieri, S, Bencivelli, W, Silman, A J, DʼAngelo, S, Cerinic, M Matucci, Belch, J F, Black, C M, Becvar, R, Bruhlman, P, Cozzi, F, Czirják, L, Drosos, A A, Dziankowska, B, Ferri, C, Gabrielli, A, Giacomelli, R, Hayem, G, Inanc, M, McHugh, N J, Nielsen, H, Scorza, R, Tirri, E, van den Hoogen, F H J, and Vlachoyiannopoulos, P G

Published
2001

22. Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study

Author

Sarzi-Puttini, P., Bianchino, L., Francesca Benaglio, Tirri, R., Salaffi, F., Pomponio, G., Cerinic, M. Matucci, Govoni, M., Gerli, R., Ferraccioli, G., Bombardieri, S., Idolazzi, L., and Caporali, R.

Subjects
Adult, Male, rheumatoid arthritis, tocilizumab, rheumatoid arthritis, clinical practice, Tumor Necrosis Factor-alpha, TRUST study, Middle Aged, Antibodies, Monoclonal, Humanized, Tocilizumab, rheumatoid arthritis, TRUST study, Receptors, Interleukin-6, NO, clinical practice, Arthritis, Rheumatoid, tocilizumab, Antirheumatic Agents, Humans, Female, Aged
Abstract

To describe the effectiveness and safety of tocilizumab (TCZ), an interleukin-6 receptor inhibitor, in a cohort of patients with rheumatoid arthritis (RA) recruited in clinical practice.TRUST was an observational study in RA patients who started treatment with TCZ in the 6 months prior to site activation and were still on treatment at start of study; patients were followed up to 12 months after the first TCZ infusion.322 RA patients were enrolled in 59 Italian centres (mean age: 55.8 years; mean disease duration: 120.5 months; baseline DAS28: 5.3). After 6 months of TCZ treatment, patients achieving low disease activity (DAS28 ≤3.2; 57.52%) or disease remission (DAS282.6; 38.05%) were 216 out of 226 patients with available DAS28 (p0.001). No statistically significant differences were found in mean DAS28 and HAQ score changes from baseline (start of TCZ treatment) to study end between patients previously inadequately responding to disease-modifyinganti-rheumatic drugs (DMARD-IR) or to DMARDs plus tumour necrosis factor inhibitors (DMARD +TNFi-IR): both patient populations responded to TCZ. A statistically significant decrease in mean VAS Fatigue score (48.4 vs. 34.7; p=0.0025) at month 6 was observed. In patients treated with TCZ as monotherapy (32.61%), DAS28, VAS fatigue and HAQ scores decreased from baseline to any post-baseline time point. Overall, 62 patients (19.3%) prematurely discontinued TCZ treatment, 24 (7.5%) for safety reasons. Drug-related adverse events occurred in 92 patients (28.6%) (mostly 3 hypercholesterolaemia and leucopenia) and drug-related serious adverse events in 11 patients (3.4%).This study confirms the good effectiveness and safety profile of TCZ in real life RA patient care.

Published
2017

24. PERFORMANCE OF THE EULAR SYSTEMIC SCLEROSIS IMPACT OF DISEASE (SCLEROID) QUESTIONNAIRE AS A PATIENT REPORTED OUTCOME MEASURE FOR PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS.

Author

Dobrota, R., Garaiman, A., Fligelstone, K., Kennedy, A., Roennow, A., Allanore, Y., Carreira, P., Czirják, L., Denton, C. P., Hesselstrand, R., Sandqvist, G., Kowal-Bielecka, O., Bruni, C., Cerinic, M. Matucci, Mihai, C., Gheorghiu, A. M., Müller-Ladner, U., Sexton, J., Kvien, T. K., and Heiberg, T.

Published
2023
Full Text
View/download PDF

27. Intravenous immunoglobulins control scleromyxoedema. (Concise Report)

Author

Righi, A, Schiavon, F, Jablonska, S, Doria, A, Blasczyk, M, Rondinone, R, Todesco, S, and Cerinic, M Matucci

Subjects
Systemic scleroderma -- Drug therapy, Immunoglobulins -- Health aspects, Scleroderma (Disease) -- Drug therapy, Health, Drug therapy, Health aspects
Abstract

Background: Scleromyxoedema is a variant of papular mucinosis affecting the skin and internal organs. The different therapeutic approaches proposed for scleromyxoedema are still unsatisfactory. Intravenous immunoglobulin, (IVIg) has been successfully [...]

Published
2002

29. Nedd5, a novel autoantigen in systemic sclerosis

Author

Alessandri, C., Germano, V., Valeria RICCIERI, Cinelli, M., Guiducci, S., Rogal, V., Colasanti, T., Delunardo, F., Margutti, P., Ortona, E., Cerinic, M. Matucci, and Valesini, G.

Published
2007

31. Vitamin D levels in children, adolescents, and young adults with juvenile-onset systemic lupus erythematosus: a cross-sectional study.

Author

Stagi, S, Cavalli, L, Bertini, F, Martino, M de, Cerinic, M Matucci, Brandi, ML, and Falcini, F

Subjects
SYSTEMIC lupus erythematosus, DUAL-energy X-ray absorptiometry, DENSITOMETRY, X-ray spectroscopy, LUMBAR vertebrae, PATIENTS
Abstract

The article presents a study which aims to assess serum 25-hydroxyvitamin D (25(OH)D) on juvenile systemic lupus erythematosus (JSLE) patients. It states that the study was conducted to 45 Caucasian JSLE patients who underwent dual-energy X-ray absorptiometry (DXA) scans of the lumbar spine. It is inferred that Vitamin D supplementation is helpful to normalize bone mass and quality in subjects with JSLE.

Published
2014
Full Text
View/download PDF

33. Cross-sectional and longitudinal evaluation of bone mass and quality in children and young adults with juvenile onset systemic lupus erythematosus (JSLE): role of bone mass determinants analyzed by DXA, PQCT and QUS.

Author

Stagi, S, Cavalli, L, Bertini, F, Cerinic, M Matucci, Brandi, M Luisa, and Falcini, F

Subjects
BONE growth, SYSTEMIC lupus erythematosus diagnosis, BONE densitometry, DISEASE risk factors, OSTEOPOROSIS, OSTEOPOROSIS treatment, DIPHOSPHONATES
Abstract

The article examines the bone mass and quality among young adults and adolescents with juvenile onset systemic lupus erythematosus (JSLE) and determines the primary predictors of reduced bone mineral density and bone quality. The study shows the low bone mass of the JSLE patients with high osteoporosis risk in their early adulthood. It notes the consideration of the therapeutic approaches to osteoporosis such as bisphosphonates.

Published
2014
Full Text
View/download PDF

35. Randomized, Prospective, Placebo-Controlled Trial of Bosentan in Interstitial Lung Disease Secondary to Systemic Sclerosis.

Author

Seibold, J. R., Denton, C. P., Furst, D. E., Guillevin, L., Rubin, L. J., Wells, A., Cerinic, M. Matucci, Riemekasten, G., Emery, P., Chadha-Boreham, H., Charef, P., Roux, S., and Black, C. M.

Subjects
INTERSTITIAL lung diseases, DRUGS, SYSTEMIC scleroderma, RANDOMIZED controlled trials, PLACEBOS, CARBON monoxide, THERAPEUTICS
Abstract

The article presents a study which examined the effectiveness of bosentan in the treatment of systemic sclerosis-related interstitial lung disease in a 12-month randomized, placebo-controlled trial. According to the results of the study, there was no improvement in exercise capacity in a group treated with bosentan compared with the placebo group. The study also showed the stability of forced vital capacity and diffusing capacity for carbon monoxide in both groups.

Published
2010
Full Text
View/download PDF

36. Psoriatic disease: concepts and implications.

Author

Scarpa, R., Altomare, G., Marchesoni, A., Balato, N., Cerinic, M. Matucci, Lotti, T., Olivieri, I., Vena, G. A., Salvarani, C., Valesini, G., and Giannetti, A.

Subjects
PSORIATIC arthritis, SKIN diseases, CARCINOGENESIS, HYPERLIPIDEMIA, HYPERTENSION, CARDIOVASCULAR diseases
Abstract

The article focuses on the concepts of psoriatic disease, which was introduced to provide a new perspective on psoriasis and related disorder. It mentions that the introduction of the new concept of psoriatic disease represents an opportunity to better understand the complex associations of psoriasis-related disorder at both the pathogenetic and clinical level. It says that patients with psoriasis also reveal an increased occurrence of hyperlipidaemia, hypertension, and cardiovascular disease.

Published
2010
Full Text
View/download PDF

37. Juvenile psoriatic arthritis and comorbidities: report of a case associated with enthesitis and celiac disease.

Author

Prignano, F., Bonciani, D., Bandinelli, F., Cerinic, M. Matucci, and Lotti, T.

Subjects
CASE studies, PSORIATIC arthritis, CELIAC disease in children, JUVENILE idiopathic arthritis
Abstract

The present authors report the case of a 9-year-old boy affected by psoriasis, juvenile psoriatic arthritis, enthesitis, and celiac disease. The signs and symptoms of the different comorbitities appeared at different times in the clinical history, complicating the overall diagnostic and therapeutic procedures. Cooperation between dermatologists and rheumatologist is mandatory in similar cases, where sophisticated technology and teams with specialized and integrated knowledge are required. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

40. Familial scleroderma: Do environmental factors, genes and microchimerism share the same relevance?

Author

Del Rosso, A., Pignone, A., Giacomelli, R., and Cerinic, M. Matucci

Subjects
SYSTEMIC scleroderma, GENES
Abstract

Editorial. Argues that environmental factors, genes and microchimerism share the same relevance in the occurrence of familial scleroderma. Studies that have investigated the familial occurrence of localized scleroderma; Environmental factors and host factors that inducesreactivity to selected self cellular and cell surface constituents; Importance of environmental factors in the development of systemic scleroderma.

Published
2001
Full Text
View/download PDF

48. Pulmonary fibrosis in systemic sclerosis: is treatment with cyclophosphamide more effective than placebo?

Author

Miniati, I., Cerinic, M. Matucci, and Farsarakis, Jasmine

Subjects
*DRUG efficacy, *PLACEBOS, *PULMONARY fibrosis, *SYSTEMIC scleroderma, *THERAPEUTICS
Abstract

The article discusses a clinical study that compares the effectiveness between cyclophosphamide and placebo in treating pulmonary fibrosis in patients with systemic sclerosis. The study reveals that pulmonary fibrosis is one major cause of death of systemic sclerosis patients. Result demonstrates no significant improvement in primary or secondary outcome measures in the drug group as compared to placebo.

Published
2007
Full Text
View/download PDF

49. Polyneuropathy as initial manifestation of systemic sclerosis (scleroderma).

Author

Knupp-Oliveira, S., Cerinic, M. Matucci, and Cerinic, M M

Subjects
*POLYNEUROPATHIES, *SYSTEMIC scleroderma, *IMMUNOGLOBULINS
Abstract

We report the first case of a young female patient who developed a sensory-motor polyneuropathy, without any skin or internal involvement characteristic of SSc, but with a serological positivity of antitopoisomerase I antibodies. After 4 years she developed a rapid skin tightening with lung involvement, in a full blown picture of the diffuse subset of SSc. The case suggests that the peripheral nervous system deserves more attention, in particular in the earliest phase of SSc. [ABSTRACT FROM AUTHOR]

Published
1999
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results